Jianxiang Wang, Dr
Institute of Hematology & Blood Diseases Hospital, China · Institute of Hematology & Blood Diseases Hospital, Tianjin, China · Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jianxiang Wang, Dr as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 13:38 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06481228 · Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Positive Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06481241 · Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALLInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult · principal investigator
- N/ANCT06461351 · Long-term Observational Study of Patients Treated With Inaticabtagene Autoleucel InjectionJuventas Cell Therapy Ltd. · recruiting · B-cell Tumors · principal investigator
- N/ANCT06450067 · Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaJuventas Cell Therapy Ltd. · recruiting · B-cell Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT05660473 · Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · recruiting · Precursor Cell Lymphoblastic Leukemia-Lymphoma · principal investigator
- Ph2NCT05594784 · Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALLInstitute of Hematology & Blood Diseases Hospital, China · completed · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia · principal investigator
- Ph1/Ph2NCT05579132 · A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)MSD R&D (China) Co., Ltd. · recruiting · Acute Lymphoblastic Leukemia · principal investigator
- Ph2NCT04684147 · Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · recruiting · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT04230473 · A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Acute Lymphoblastic LeukemiaJuventas Cell Therapy Ltd. · completed · Relapsed or Refractory Acute Lymphoblastic Leukemia · principal investigator
- Ph1NCT03560908 · Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 MutationInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · Relapsed AML, T(8;21), C-KIT Mutation · principal investigator
- Ph1/Ph2NCT03031262 · Efficacy and Safety of Chidamide in CBF LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1/Ph2NCT03021395 · Efficacy of Decitabine in Clearance of MRDInstitute of Hematology & Blood Diseases Hospital, China · withdrawn · AML · principal investigator
- Ph3NCT03021330 · Efficacy of Intermediate-Dose Cytarabine Induction Regimen in Adult AMLInstitute of Hematology & Blood Diseases Hospital, China · active not recruiting · AML · principal investigator
- Ph1NCT02975687 · CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Lymphoblastic Leukemia, Adult B-Cell, Acute Lymphoblastic Leukaemia Recurrent · principal investigator
- Ph2NCT02937662 · Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AMLInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute Myeloid Leukemia · principal investigator
- Ph2NCT02523976 · Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic LeukemiaInstitute of Hematology & Blood Diseases Hospital, China · completed · Acute,Leukemia, Lymphoid · principal investigator
- Ph4NCT02267993 · Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML PatientsInstitute of Hematology & Blood Diseases Hospital, China · completed · Thrombocytopenia · principal investigator
- Ph2NCT01503502 · A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous LeukemiaJiangsu HengRui Medicine Co., Ltd. · unknown · Myelogenous Leukemia, Chronic · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 13:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in childhood acute lymphoblastic leukemia.